Xilio Therapeutics Enhances Board with Two New Directors

Xilio Therapeutics (XLO) has provided an update.

Xilio Therapeutics, Inc. has expanded its Board of Directors to nine members, welcoming James Shannon, M.D., as a Class I director, and Aoife Brennan, M.D., as a Class III director, each to serve until their successors are chosen or until an earlier departure. Dr. Shannon joins the Nominating and Corporate Governance Committee, while Dr. Brennan steps onto the Audit Committee. Both directors will be compensated according to the company’s established non-employee director policy and will be covered under the standard indemnification agreement.

Find detailed analytics on XLO stock on TipRanks’ Stock Analysis page.